The company's IT capabilities have been evolving in scope to more comprehensively encompass the coordination of a firm’s assets and internal processes and their interfirm transactions and relationships. The ability to acquire, deploy, combine, and reconfigure IT resources is crucial in support and enhancement of business strategies and work processes. The management emphasizes the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. IT capability, defined as the IT function’s competence to effectively support business needs, has become a key factor in transforming the firm into a competitive force. The firm’s IT capabilities represent the application of physical or intangible IT resources such as technology, knowledge, practices, relationships, management skills, business process understanding, and human resources to further organizational goals. The company engages in various forms of business development activities, including licensing arrangements, co-development agreements, and joint ventures, which are essential for enhancing its product pipeline and overall business strategy. The integration of new technologies and the ability to manage information effectively are critical in navigating the complexities of the pharmaceutical industry, particularly in the context of regulatory approvals and market dynamics. The company faces challenges related to the integration of new personnel and operations from acquisitions, which may impact its ability to realize expected benefits from business development transactions. The management continuously evaluates liquidity and capital resources to ensure adequate financing for capital requirements, including investments in technology and infrastructure that support operational efficiency and strategic resource allocation. The firm’s commitment to investing in manufacturing capacity and technology infrastructure is aimed at meeting the growing demand for its products while enhancing operational flexibility. The establishment of payment limits or other restrictions by drug affordability review boards and other state-level actors could adversely impact the company’s business and consolidated results of operations, emphasizing the need for robust IT governance and strategic management practices. The firm remains focused on protecting its competitive positioning by leveraging its IT capabilities to enhance business performance and respond to market changes effectively. The evolving landscape of pharmaceutical pricing, reimbursement, and access reforms necessitates a strategic alignment of IT resources to support decision-making processes and improve operational efficiencies. The management recognizes that the ability to provide accurate, timely, and reliable information is essential for maintaining competitive advantage and achieving business objectives. The company’s strategic resource allocation decisions are influenced by external factors, including regulatory changes and market competition, underscoring the importance of IT capabilities in navigating these challenges.